Totowa

Early diagnosis of cancer can lead to better treatment results, higher chances of survival, and reduced care costs. Monitoring cancer in populations at risk is an important part of early detection. The HMH Hennessey Institute for Cancer Prevention and Applied Molecular Science (HICAP) offers clinical services for cancer screening and risk evaluation, along with research focused on cancer risk and prevention. The CanScan registry is designed to collect data prospectively from participants through questionnaires and other non-research assessments for those who agree to participate. This registry aims to improve understanding of cancer risk, screening methods, and diagnostic processes. Participants who join the CanScan registry will provide health information over time to support research and clinical services related to cancer prevention. The registry gathers data from questionnaires and routine clinical assessments collected during participation in the HICAP program or for those at increased cancer risk. There are no specific treatment interventions or experimental therapies involved in this registry study. During the study, participants will complete questionnaires about their health and cancer risk factors. Researchers will collect and analyze this data to assess the rate of pathogenic germline variants over a period of 10 years from the start of the study. This long-term data collection helps improve knowledge about cancer predisposition and supports better screening and prevention strategies. Participants contribute by allowing their information to be included in this community-based cancer prevention registry.

The goal of this study is to find out whether a system that uses trained detection dogs and artificial intelligence (AI) can identify breast cancer from a person's breath. Women who are scheduled to have routine breast cancer screening, such as a mammogram, ultrasound, or a biopsy for a possible cancer, will be invited to take part. Participants will be asked to breathe into a surgical mask to collect a breath sample. The mask will be sent to a special laboratory, where trained dogs and an AI-based system will check the sample for signs of breast cancer. The results from the dogs and AI will be compared to the actual results from the medical screening or biopsy to see how accurate the system is at detecting breast cancer.

Researchers are evaluating the efficacy, safety, and tolerability of IMVT-1402 in adults diagnosed with mild to severe generalized myasthenia gravis. This Phase 3 study focuses on participants classified as Class II, III, or IVa by the Myasthenia Gravis Foundation of America and who have a certain level of daily living impairment due to their condition. Participants will receive either IMVT-1402 or a placebo through weekly subcutaneous injections. The study includes multiple treatment periods: an initial 12-week period where participants receive either Dose 1 or Dose 2 of IMVT-1402 or placebo, followed by additional periods where IMVT-1402 is administered weekly for up to 14 weeks and then 52 weeks, depending on the dose group. Throughout the study, participants will be regularly assessed for changes in their MG activities of daily living score from baseline through week 12. Safety and tolerability will also be monitored during and after treatment. Participants must be able to comply with study procedures and provide informed consent, with a total participation age range of 18 to 80 years.